CRISPR
CourageAS
CourageAS is exploring an investigational Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) approach to treating Angelman syndrome using a non-viral delivery strategy.
Funded
Pre-clinical
Discovery & Dev
Pre-clinical
Phase 1
Phase 2
Phase 3
To patients
-
progress mobile progress mobile progress mobile progress mobile progress mobile progress mobile
Disclaimer
This website contains information for a broad audience and may include information on current and upcoming programs that are not yet approved or accessible The information provided is for general informational purposes only and is not intended as medical advice, diagnosis, or treatment. While FAST strives to provide accurate and up-to-date information, the content on this site may not always reflect the most current research or clinical guidelines. The inclusion of clinical trial information, treatments or specific healthcare providers does not imply endorsement, recommendation or guarantee of safety, efficacy, or availability. Reliance on any information provided by this website is solely at your own risk. FAST disclaims any liability for any errors or omissions in the information provided or for any decisions made based on this information. For personalized medical advice or specific health concerns including participation in any clinical trial, please consult a qualified healthcare professional.
FAST Pillar
Therapeutic Approach
A gene editing tool that utilizes a guide RNA (gRNA) to recognize a specific section of DNA or RNA and directs an enzyme (nuclease) to cut at a specific section in the DNA or RNA. Designing a CRISPR that affects the UBE3A-ATS could potentially allow the paternal UBE3A gene to be turned on. It could also be used to edit a mutation in a gene, known as base editing.
Collaborators
Program Overview
In October 2023, the National Institutes of Health awarded the first phase of a roughly $40m grant to Yale University to advance a novel CRISPR-based gene-editing delivery platform for the targeted treatment of neurogenetic diseases.
The two diseases being targeted in the project are Angelman syndrome and H1-4 (HIST1H1E) syndrome. The project team named under the grant includes representatives from Dr. Yong-Hui Jiang’s team and Dr. Jiangbing Zhou’s team at Yale, Dr. Elizabeth Berry-Kravis’ team at RUSH, and Dr. Allyson Berent and Jennifer Panagoulias from the Foundation for Angelman Syndrome Therapeutics (FAST).
The grant, from the NIH Common Fund, is part of a two-phase program with a total proposed budget of approximately $40 million over 5 years. The first phase, worth $26.5 million, is dedicated to generating all preclinical data and other key components towards a clinical trial for both diseases. The second phase, worth approximately $13.4 million, is intended to fund the Phase 1/2 clinical trial itself. The award of this second phase is contingent upon successful completion of the first phase.
Recent Updates
-
Oct 2023
Read MoreThe National Institutes of Health awarded the first phase of a roughly $40m grant to Yale University to advance a novel CRISPR-based gene-editing delivery platform for the targeted treatment of neurogenetic diseases.
Media
-
From Benchside to Bedside: Collaboration Leads to Acceleration for Novel Delivery of CRISPR Technology